[1]王结珍,梁培松.基于TCGA 数据库构建肝细胞癌双硫死亡相关基因（DRGs）预后风险模型及评价[J].现代检验医学杂志,2024,39(02):86-90.[doi:10.3969/j.issn.1671-7414.2024.02.016]
　WANG Jiezhen,LIANG Peisong.Construction and Evaluation of the Disulfidptosis-Related Genes (DRGs) Prognostic Risk Model for Hepatocellular Carcinoma Based on TCGA Database[J].Journal of Modern Laboratory Medicine,2024,39(02):86-90.[doi:10.3969/j.issn.1671-7414.2024.02.016]
点击复制

基于TCGA 数据库构建肝细胞癌双硫死亡相关基因（DRGs）预后风险模型及评价()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年02期
页码:
86-90
栏目:
论著
出版日期:
2024-03-15

文章信息/Info

Title:
Construction and Evaluation of the Disulfidptosis-Related Genes (DRGs) Prognostic Risk Model for Hepatocellular Carcinoma Based on TCGA Database
文章编号:
1671-7414（2024）02-086-05
作者:
王结珍; 梁培松
（中山市人民医院检验医学中心，广东中山 528403）
Author(s):
WANG Jiezhen; LIANG Peisong
(Medical Laboratory Center，Zhongshan People’s Hospital, Guangdong Zhongshan 528403，China)
关键词:
肝细胞癌; 癌症基因组图谱; 双硫死亡相关基因; 预后风险模型
分类号:
R735.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.02.016
文献标志码:
A
摘要:
目的 基于癌症基因组图谱（the cancer genome atlas，TCGA） 数据库构建肝细胞癌（hepatocellularcarcinoma，HCC）双硫死亡相关基因（disulfidptosis-related genes，DRGs）预后风险模型及评价。方法 通过生物信息学方法分析TCGA 数据库中371 例HCC 样本及50 例癌旁样本中15 个DRGs 的表达情况，并进行基因本体（geneontology，GO）功能注释和京都基因和基因组百科全书（Kyoto encyclopedia of genes and genomes，KEGG）富集分析、Kaplan-Meier（KM）生存分析；通过单因素COX 回归分析筛选出有统计学意义的DRGs，通过LASSO 回归分析及多因素COX 回归分析筛选出关键DRGs 构建预后风险模型，并根据风险评分将HCC 患者分为高风险组和低风险组，制作KM 生存曲线和时间依赖的受试者工作特征（receiver operator characteristic，ROC）曲线进行验证评价。结果 与癌旁样本相比，HCC 样本15 个DRGs 中FLNA，MYH9，TLN1，ACTB，MYL6，CAPZB，DSTN，ACTN4，SLC7A11，INF2，CD2AP，PDLIM1 和FLNB 均表达上调，且差异具有统计学意义（t=1 793 ～ 6 310，均P<0.001）；经GO 功能注释和KEGG 富集分析显示，DRGs 主要与肌动蛋白细胞骨架和细胞黏附相关的生物过程或途径密切相关。经KM 生存分析结果显示，SLC7A11，INF2，CD2AP，MYL6，ACTB 高表达组生存率低于低表达组[HR=1.46(1.03~2.07) ～ 1.93(1.36~2.75)，均P<0.05]。通过单因素COX 回归分析、LASSO 分析及多因素COX 回归分析构建预后风险模型riskscore=(0.247×SLC7A11)+(0.289×INF2)+(0.076×CD2AP)+(0.06×MYL6)；计算样本的风险评分，风险评分越高，预后不良的HCC 患者人数越多；KM 生存分析显示高风险组的总生存率比低风险组低；1，3，5 年的AUC 值分别为0.709，0.661 和0.648；通过多因素COX 回归分析表明SLC7A11[HR=1.832(1.274~2.636)，P=0.001] 是独立的预后危险因素。结论 四个DRGs 构建的预后风险模型在预测HCC 患者预后情况有一定的作用。
Abstract:
Objective To construct and evaluate a disulfidptosis-related genes (DRGs) prognostic risk model for hepatocellular carcinoma (HCC) based on the cancer genome atlas (TCGA) database. Methods The expression of 15 DRGs in 371 HCC samples and 50 adjacent cancer samples in the TCGA database was analyzed using bioinformatics methods, and then gene ontology (GO) functional annotation, Kyoto encyclopedia of genes and genomes (KEGG) enrichment analysis and Kaplan- Meier (KM) survival analysis were performed. Statistical significant DRGs were screened through univariate COX regression analysis, and key DRGs were selected through LASSO regression analysis and multivariate COX regression analysis to construct a prognostic risk model. HCC patients were divided into high-risk and low-risk groups based on risk scores, and the KM survival curves and time-dependent receiver operator characteristic (ROC) curves were created to validate and evaluate prognostic risk models. Results Compared with the adjacent cancer samples, FLNA, MYH9, TLN1, ACTB, MYL6, CAPZB, DSTN, ACTN4, SLC7A11, INF2, CD2AP, PDLIM1, and FLNB were all upregulated in the 15 DRGs of HCC samples, and the differences were significant (t=1 793 ～ 6 310, all P<0.001). According to GO functional annotation and KEGG enrichment analysis, DRGs were closely related to biological processes or pathways related to actin cytoskeleton and cell adhesion. The results of KM survival analysis showed that the survival rate of the high expression group of SLC7A11, INF2, CD2AP, MYL6, and ACTB were lower than that of the low expression group[HR=1.46(1.03~2.07) ～ 1.93(1.36~2.75), all P<0.05]. Univariate COX regression analysis, LASSO analysis, and multivariate COX regression analysis were used to construct a prognostic risk model, with risk score=(0.247×SLC7A11)+(0.289×INF2)+(0.076×CD2AP)+(0.06×MYL6). The risk score of the sample in this model was calculated, and the higher the risk score, the more HCC patients with poor prognosis. KM survival analysis showed that the overall survival rate of the high-risk group was lower than that of the low-risk group. The AUC values for 1, 3, and 5 years were 0.709, 0.661, and 0.648, respectively. Multivariate COX regression analysis showed that SLC7A11 [HR=1.832(1.274~2.636), P=0.001] was an independent prognostic risk factor. Conclusion The prognostic risk model was constructed by four DRGs, which has a certain role in predicting the prognosis of HCC patients.

参考文献/References:

[1] CAO Wei, CHEN Hongda, YU Yiwen, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J].Chinese Medical Journal, 2021, 134(7): 783-791.
[2] SHAO Dongpu, SHI Lei, JI Honglei. Disulfidptosis:disulfide stress mediates a novel cell death pathway via actin cytoskeletal vulnerability[J]. Molecules and Cells, 2023, 46(7): 414-416.
[3] ZHENG Peijie, ZHOU Chuntao, DING Yuemin, et al. Disulfidptosis: a new target for metabolic cancer therapy[J]. Journal of Experimental & Clinical Cancer Research, 2023, 42(1): 103.
[4] WANG Tianbing, GUO Kai, ZHANG Di, et al. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile[J]. International Immunopharmacology, 2023,120: 110368.
[5] LIU Xiaoguang, NIE Litong, ZHANG Yilei, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis[J]. Nature Cell Biology, 2023,25(3): 404-414.
[6] 卢美红, 杨曙梅, 王峰, 等. 血清miRNA-574-3p,AFP,IGF-2 水平联合检测在肝癌早期诊断中的价值研究[J]. 现代检验医学杂志, 2022, 37(2): 33-36. LU Meihong, YANG Shumei, WANG Feng, et al. Study on the value of combined detection of serum miRNA-574-3p, AFP and IGF-2 levels in the early diagnosis of liver cancer[J]. Journal of Modern Laboratory Medicine, 2022, 37(2): 33-36.
[7] WANG Zhitang, DU Xianqiang, LIAN Weibin, et al. A novel disulfidptosis-associated expression pattern in breast cancer based on machine learning[J]. Frontiers in Genetics, 2023, 14: 1193944.
[8] LI Xiaomin, LIU Shanpeng, LI Yu, et al. Identification of disulfidptosis-related genes with immune infiltration in hepatocellular carcinoma[J]. Heliyon, 2023, 9(8):e18436.
[9] 方全, 韦花媚, 浦涧. 肌动蛋白丝细胞骨架重塑在肝细胞癌中的研究进展[J]. 右江医学, 2023, 51(4):289-293. FANG Quan, WEI Huamei, PU Jian. Research progress of actin cytoskeleton remodeling in hepatocellular carcinoma[J]. Chinese Youjiang Medical Journal,2023, 51(4): 289-293.
[10] 詹有芳, 张珏, 王鹏. 肝细胞癌患者血清SLC7A11的变化及临床意义[J]. 肝脏, 2022, 27(12): 1288-1291. ZHAN Youfang, ZHANG Jue, WANG Peng. Changes and clinical significance of serum SLC7A11 in patients with hepatocellular carcinoma[J]. Chinese Hepatology,2022, 27(12): 1288-1291.
[11] YAN Yuelong, TENG Hongqi, HANG Qinglei, et al. SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells[J]. Nature Communications, 2023, 14(1): 3673.
[12] LABAT-DE-HOZ L, ALONSO M A. The formin INF2 in disease: progress from 10 years of research[J].Cellular and Molecular Life Sciences, 2020, 77(22):4581-4600.
[13] ZHAO Yiting, ZHANG Hui, WANG Haibiao, et al. Role of formin INF2 in human diseases[J]. Molecular Biology Reports, 2022, 49(1): 735-746.
[14] KURILLA A, L?SZL? L, TAK?CS T, et al. Studying the association of TKS4 and CD2AP scaffold proteins and their implications in the partial Epithelial-Mesenchymal transition (EMT) process[J].International Journal of Molecular Sciences, 2023,24(20): 15136.
[15] ZHU Zhaozhong, GUO Yanjun, SHI Huwenbo, et al. Shared genetic and experimental links between obesityrelated traits and asthma subtypes in UK Biobank[J].Journal of Allergy and Clinical Immunology, 2020,145(2): 537-549.

相似文献/References:

[1]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
　DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(02):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
[2]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
　MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1 Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(02):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
[3]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
　RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
[4]隆绍平,邓世群,赵世元.PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究[J].现代检验医学杂志,2018,33(01):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　LONG Shao-ping,DENG Shi-qun,ZHAO Shi-yuan.Association between Downregulation of PTPN12 Protein and Recurrence and Prognosis in Patients with Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(02):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[5]毛丽萍,王跃国,王 健,等.CMIA法测定血清DCP与AFP对肝细胞癌的诊断价值[J].现代检验医学杂志,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
　MAO Li-ping,WANG Yue-guo,WANG Jian,et al.Diagnostic Value of the Serum DCP and AFP Determined by CMIA in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(02):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
[6]吴良银a,李文丽b,刘 俊a.肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析[J].现代检验医学杂志,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
　WU Liang-yina,LI Wen-lib,LIU Juna.Bioinformatics Analysis of Long-Chain Non-Coding RNA Related to Survival and Prognosis in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2019,34(02):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
[7]吴良银a,李文丽b,刘　俊b.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
　WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(02):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[8]陈 偲,李忠辉a,王 颖b.miR-198 通过靶向ZEB2 调控EMT 过程抑制肝癌细胞增殖和迁移的机制研究[J].现代检验医学杂志,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
　CHEN Si,LI Zhong-huia,WANG Yingb.Study on the Mechanism of miR-198 Inhibiting the Proliferation and Migration of Hepatoma Cells by Regulating EMT Process by Targeting ZEB2[J].Journal of Modern Laboratory Medicine,2022,37(02):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
[9]王 路,叶 莎,韩 霞,等.循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J].现代检验医学杂志,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
　WANG Lu,YE Sha,HAN Xia,et al.Meta-Analysis of the Diagnostic Value of Circulating Exosomes miRNA Detection for Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(02):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[10]时晓晓a,董 翔a,于若卉b,等.miR-203a-3p 靶向GLS1 调控HCC 细胞增殖、迁移、侵袭的机制研究[J].现代检验医学杂志,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
　SHI Xiao-xiaoa,DONG Xianga,YU Ruo-huib,et al.Mechanism of miR-203a-3p Targeting GLS1 to Regulate the Proliferation, Migration and Invasion of HCC Cells[J].Journal of Modern Laboratory Medicine,2022,37(02):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]

备注/Memo

备注/Memo:
作者简介：王结珍（1985-），女，本科，副主任技师，研究方向：临床检验，E-mail：wanglei8511@163.com。
通讯作者：梁培松(1976-)，男，本科，主任技师，主要从事临床基础免疫工作，E-mail：mark113388@163.com。
更新日期/Last Update: 2024-03-15